维得利珠单抗由静脉转为皮下给药后的持续性、安全性与药代动力学:法国前瞻性全国队列研究
这项法国多中心前瞻性全国队列研究纳入337例临床缓解的UC或CD患者,评估由静脉维得利珠单抗(IV-VDZ)转为皮下制剂(SC-VDZ)后的持续性、疗效、药代动力学与安全性。主要终点第52周SC-VDZ持续性为84%(95%CI 80-88),UC与CD间无显著差异(p=0.36);54%患者报告至少1例不良事件,最常见为注射部位反应(20%)和感染(17%),25例(7%)因不良事件停用SC-VDZ。
要点
- 第52周SC-VDZ持续性84%(95%CI 80-88),UC与CD间无显著差异(p=0.36)
- 10%患者需增加SC-VDZ剂量,其中16%因持续失应答最终停用维得利珠单抗
- 54%报告至少1例不良事件,注射部位反应20%、感染17%,7%因不良事件停用
核心结论
- 在这项多中心队列中,IBD患者由IV-VDZ转为SC-VDZ后1年持续性为84%。
研究设计与样本
- 多中心前瞻性法国全国队列研究,纳入2022至2024年间由IV-VDZ转为SC-VDZ的临床缓解UC或CD患者。
- 共分析337例患者,其中UC 246例(73%)、CD 91例(27%),214例(64%)采用标准IV-VDZ方案。
- 主要终点为第52周SC-VDZ持续性;疾病相关手术、重复或延长(>14天)激素疗程及失访者视为非持续。
主要发现
- 第52周SC-VDZ持续性为84%(95%CI 80-88),UC与CD间无显著差异(p=0.36)。
- 研究期间32例(10%)增加SC-VDZ剂量(216 mg每周或108 mg每2周),其中17例(53%)原为标准IV-VDZ方案。
- 持续与非持续患者的维得利珠单抗药物水平在整个研究期间相似。
- 183例(54%)报告至少1例不良事件,最常见为注射部位反应(20%)和感染(17%),25例(7%)因此停用SC-VDZ。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM: We conducted a prospective study to evaluate the persistence, efficacy, pharmacokinetics, and safety of subcutaneous VDZ (SC-VDZ) after switching from the intravenous (IV) route. METHODS: All patients with ulcerative colitis (UC) or Crohn's disease (CD) in clinical remission who switched from IV-VDZ to SC-VDZ between 2022 and 2024 were included in this multicentric prospective French national cohort study. Primary endpoint was SC-VDZ persistence at Week 52. Patients who had a disease-related surgery, repeated or prolonged (> 14 days) steroid courses, and those who were lost to follow-up were considered non-persistent. RESULTS: Among the 337 patients analysed, 246 (73%) had UC and 91 (27%) CD; 214 (64%) were on a standard IV-VDZ regimen. At Week 52, SC-VDZ persistence was 84% [95% confidence interval: 80-88], with no significant difference between diseases (p = 0.36). During the study period, 32 patients (10%) had a dose increase of SC-VDZ (either to 216 mg weekly or to 108 mg 2-weekly), including 17 (53%) who had been on a standard IV-VDZ regimen, and five (16%) eventually stopped VDZ due to persistent loss-of-response despite dose increase. Twelve out of 16 patients were successfully switched back to IV-VDZ. Vedolizumab drug levels were similar between persistent and non-persistent patients throughout the study period. A total of 183 patients (54%) reported at least one AE, most frequently injection-site reactions (20%) and infections (17%), leading to SC-VDZ discontinuation in 25 patients (7%). CONCLUSION: In this multicentric cohort, the persistence at 1 year from switch to SC-VDZ in IBD patients was 84%.
引用
- Hupé M, Mathieu N, Amiot A, et al. Persistence, Safety and Pharmacokinetics of Vedolizumab After Switching to the Subcutaneous Route in a Prospective French National Cohort Study. Aliment Pharmacol Ther. 2026. PMID: 42802497. doi:10.1111/apt.70986
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。